Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Lymphoma, AIDS-Related 1 Lymphoma 1 HIV Infections 1 Acquired Immunodeficiency Syndrome 1

Interventions

Docetaxel 292 Prednisone 241 enzalutamide 195 Leuprolide 185 Radiotherapy 179 Abiraterone Acetate 170 Magnetic Resonance Spectroscopy 163 bicalutamide 141 Goserelin 138 Androgen Antagonists 121 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108 Radiosurgery 108 apalutamide 93 abiraterone 83 gallium 68 PSMA-11 81 Specimen Handling 73 darolutamide 67 Surveys and Questionnaires 64 Gonadotropin-Releasing Hormone 63 Triptorelin Pamoate 58 Radiation 57 Biopsy 57 Brachytherapy 54 cabazitaxel 53 Standard of Care 51 Radiotherapy, Intensity-Modulated 51 Zoledronic Acid 50 pembrolizumab 49 luprolide acetate gel depot 49 Flutamide 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Genes × Clear all

NCT03152448 2022-06-13

P-PROVE

Myriad Genetic Laboratories, Inc.

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡